Treating obesity with muscarinic receptor M
Provided are methods of treating obesity and effecting desired weight loss or preventing undesired weight gain by administration of a preferential muscarinic acetylcholine receptor M 1 antagonist, optionally with at least one antidepressant other than a selective muscarinic acetylcholine receptor M 1 antagonist. The preferential muscarinic acetylcholine receptor M 1 antagonist, optionally can be administered with an anti-obesity agent, for example, an anorexiant. The invention also provides for pharmaceutical compositions and kits for administration of at least one selective muscarinic acetylcholine receptor M 1 antagonist in combination with at least one antidepressant other than a selective muscarinic acetylcholine receptor M 1 antagonist.
1. A method for promoting weight loss or facilitating maintenance of a stable weight, the method comprising co-administering to an obese or overweight human individual in need thereof telenzepine and sertraline for at least 80 days to effectuate weight loss, wherein the telenzepine is administered at a dose of about 0.5 mg per day to about 10 mg per day and the sertraline is administered at a dose of about 50 mg per day to about 200 mg per day, whereby weight loss is promoted or maintenance of a stable weight is facilitated.
2. The method of claim 1 , wherein the telenzepine and the sertraline are administered concurrently.
3. The method of claim 2 , wherein the telenzepine and the sertraline are administered as an admixture.
4. The method of claim 1 , wherein the telenzepine and the sertraline are administered sequentially.
5. The method of claim 1 , wherein the telenzepine is administered at a dose of about 1 mg per day to about 5 mg per day.
6. The method of claim 1 , wherein the sertraline is administered at a dose of about 100 mg per day to about 150 mg per day.
7. The method of claim 1 , wherein the telenzepine is administered with a meal.
8. The method of claim 1 , wherein one or both of the telenzepine and the sertraline are administered in a sustained-release formulation.
9. The method of claim 1 , wherein the telenzepine and the sertraline are co-administered for at least 150 days.
10. The method of claim 1 , wherein the telenzepine and the sertraline are co-administered for at least 200 days.